HIA
DNLI icon

HFM Investment Advisors’s Denali Therapeutics DNLI Stock Holding History

HFM Investment Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283 Buy
11
+6
+120% +$123 ﹤0.01% 1134
2026
Q1 		$96 Sell
5
-4
-44% -$80 ﹤0.01% 1123
2025
Q4 		$149 Buy
9
+7
+350% +$118 ﹤0.01% 1103
2025
Q3 		$29 Sell
2
-1
-33% -$14 ﹤0.01% 1242
2025
Q2 		$42 Buy
+3
New +$42 ﹤0.01% 1231

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HFM Investment Advisors's DNLI Position: Q2 2026 in Review

HFM Investment Advisors increased its Denali Therapeutics (DNLI) stake by 120% in Q2 2026, buying an estimated $123 and bringing the position to 11 shares worth $283. The position accounts for ﹤0.01% of the portfolio, ranked #1134.

HFM Investment Advisors first reported a position in DNLI in Q2 2025 and has held it in 5 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • HFM Investment Advisors held 11 shares of Denali Therapeutics worth $283 as of Q2 2026.
  • HFM Investment Advisors bought 6 Denali Therapeutics shares in Q2 2026, an estimated $123.
  • Denali Therapeutics made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #1134 holding.
  • HFM Investment Advisors first reported a position in Denali Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.